EIM
TVRD

Essex Investment Management’s Tvardi Therapeutics TVRD Stock Holding History

Essex Investment Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,541
Closed -$516K – 377
2016
Q4 		$516K Buy
+1,541
New +$495K 0.09% 246

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Essex Investment Management's TVRD Position: Q1 2017 in Review

Essex Investment Management sold out of Tvardi Therapeutics (TVRD) in Q1 2017, closing a stake of 1,541 shares — an estimated $516K sold.

Essex Investment Management first reported a position in TVRD in Q4 2016 and held it in 1 quarter. The position peaked at $516K in Q4 2016. 114 funds tracked by Wall St. Rank hold TVRD as of Q1 2017.

  • Essex Investment Management reported no remaining Tvardi Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Essex Investment Management sold 1,541 Tvardi Therapeutics shares in Q1 2017, an estimated $516K.
  • Essex Investment Management first reported a position in Tvardi Therapeutics in Q4 2016 and held it in 1 quarter.
  • Essex Investment Management's Tvardi Therapeutics position peaked at $516K in Q4 2016.
  • 114 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2017.

Based on Essex Investment Management's 13F filing for Q1 2017, filed 27 Apr 2017.